Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

about

Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.Biosimilars in paediatric inflammatory bowel disease

P2860

Q52581473-24A034A0-508B-4A68-BCB2-BA69F9190070 Q58707780-4A3C0CBD-E474-4031-800B-A574BB12FC15

P2860

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

Item

http://www.wikidata.org/entity/Q38824505

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

@en

type

Item

label

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

@en

prefLabel

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

@en

P1476

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

@en

P2093

Fanni Rencz

http://www.w3.org/2001/XMLSchema#string

Fernando Gomollón

http://www.w3.org/2001/XMLSchema#string

Jonas Halfvarson

http://www.w3.org/2001/XMLSchema#string

Krisztina B Gecse

http://www.w3.org/2001/XMLSchema#string

László Gulácsi

http://www.w3.org/2001/XMLSchema#string

Márta Péntek

http://www.w3.org/2001/XMLSchema#string

Peter L Lakatos

http://www.w3.org/2001/XMLSchema#string

Petra Baji

http://www.w3.org/2001/XMLSchema#string

Valentin Brodszky

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammatory bowel disease: clinical aspects and established and evolving therapies

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases

Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Inflammatory bowel disease

Epidemiology and natural history of inflammatory bowel diseases

The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data.

Biological treatment of Crohn's disease.

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737167.2017.1322509

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Peyrin-Biroulet

Axel Dignass

P577

2017-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28434387

http://www.w3.org/2001/XMLSchema#string

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

about

P2860

P2860

Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P50

P577

P698